Abstract
Prostate cancer (PC) is the most common malignant tumor in men. Early identification of prostate cancer may result in improved cure rates and increased life expectancies. Gleason score and clinical range at the time of diagnosis are important factors to predict prognosis and outcome after therapy but additional accurate and reliable biomarkers are warranted. Few biomarkers of prostate cancer have been successfully implemented and used in clinical practice. In this study, we sought to determine the expression of E-cadherin, beta-catenin and human epidermal receptor (HER2) in biopsy specimens of prostate cancer with perineural invasion, and correlate them with Gleason score in order to verify the relationship between those markers and prostate cancer process. Our study demonstrated abnormal expression of E-cadherin, beta-catenin and HER2. On the other hand, our results showed no correlation between Gleason score and the expression of those markers in invasive prostate cancer tissues. Other different biomarkers remain to be identified, that potentially could improve the evaluation of prognostic of the patient. Key words: Biomarkers, biopsy specimens, Gleason score, perineural invasion, prostate cancer.
Highlights
Prostate cancer (PC) is the most common malignant tumor in men and is a major research focus of Pathologists, Urologists and Uro-oncologists
When E-cadherin, beta-catenin or human epidermal growth factor receptor 2 (HER2) were considered with Gleason score (Tables 2 and 3) no correlation was observed
We focused on the expression of three tissue biomarkers in prostate cancer: E-cadherin, beta-catenin and HER2
Summary
Prostate cancer (PC) is the most common malignant tumor in men and is a major research focus of Pathologists, Urologists and Uro-oncologists. Very few biomarkers of prostate cancer have been successfully implemented and used in clinical practice. E-cadherin is down regulated in most epithelial cancers, and can be correlated to higher mobility and invasiveness of tumor cells (Veveris-Lowe et al, 2005). The gene encoding the HER2 protein is amplified in 20 to 25% of breast cancer patients and it is overexpressed in many prostate cancers (Solit and Rosen, 2007). We sought to determine the relative expression of E-cadherin, beta-catenin and HER2 in biopsy specimens of prostate cancer patients with perineural invasion and correlate them with Gleason score in order to find the relationship between those markers and prostate cancer process
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call